Research programme: topical fluorouracil - NanoCyteAlternative Names: IR fluorouracil
Latest Information Update: 16 Jul 2016
At a glance
- Originator NanoCyte
- Class Antineoplastics; Pyrimidinones; Small molecules
- Mechanism of Action Thymidylate synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Skin cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Skin-cancer in Israel (Topical)
- 17 Aug 2004 Preclinical trials in Skin cancer in Israel (Topical)